quinazolines has been researched along with alpha-aminopyridine in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (17.65) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (17.65) | 29.6817 |
| 2010's | 22 (64.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braunwald, E; Colucci, WS; Wright, RF | 1 |
| Komajda, M | 1 |
| Carlier, J; D'Orio, V; el Allaf, D | 1 |
| Andrews, V; Fishman, AP; Janicki, JS; Kinasewitz, GT; Weber, KT | 1 |
| Alfiero, R; Cocco, G; Padula, A; Rizzo, A; Strozzi, C; Tasini, MT; Urso, L | 1 |
| Cocco, G; Sfrisi, C | 1 |
| Hezky, P; Krejcí, I; Proska, J; Rádl, S | 1 |
| Daud, A; Munster, P; Spriggs, DR | 1 |
| Cai, L; Hertz, L; Li, B; Nu, W; Peng, L; Zhang, H; Zhang, S | 1 |
| Aberg, A; Andersson, G; Andrews, G; Arvai, AS; Cheshire, DR; Connolly, S; Crane, BR; Garcin, ED; Gensmantel, NP; Getzoff, ED; Hamley, PJ; Kroeger, MD; Mallinder, PR; Mete, A; Nicholls, DJ; Rosenfeld, RJ; St-Gallay, SA; Stuehr, DJ; Tainer, JA; Tinker, AC; Wallace, AV | 1 |
| Downing, JR | 1 |
| Berchuck, JE; Carr, SA; Carroll, M; Clauser, K; Davis, TN; DeAngelo, DJ; Galinsky, I; Golub, TR; Hahn, CK; Hahn, WC; Kakoza, RM; Kung, AL; Root, DE; Ross, KN; Ross, L; Schinzel, AC; Silver, SJ; Stegmaier, K; Stone, RM | 1 |
| Hussar, DA | 1 |
| Koizumi, H; Li, Q; Matsumoto, K; Mukaida, N; Nakagawa, T; Nakamura, T; Nishioka, Y; Sone, S; Takeuchi, S; Uenaka, T; Wang, W; Yamada, T; Yano, S | 1 |
| Aliagas, I; Alicke, B; Boggs, JW; Buckmelter, AJ; Choo, EF; Dinkel, V; Gloor, SL; Gould, SE; Gradl, SN; Grina, J; Gunzner-Toste, J; Hansen, JD; Hastings, G; Hatzivassiliou, G; Laird, ER; Lee, W; Mathieu, S; Moreno, D; Pulk, R; Ran, Y; Ren, L; Rudolph, J; Voegtli, WC; Wen, Z; Wenglowsky, S; Zhao, G | 1 |
| Donev, IS; Kita, K; Li, Q; Matsumoto, K; Nakagawa, T; Nakamura, T; Nishioka, Y; Shimizu, E; Sone, S; Takeuchi, S; Uenaka, T; Wang, W; Yamada, T; Yano, S | 1 |
| Ishikawa, D; Kita, K; Matsumoto, K; Mitsudomi, T; Nakagawa, T; Nakamura, T; Nanjo, S; Sano, T; Sekido, Y; Suda, K; Takeuchi, S; Uenaka, T; Yamada, T; Yano, S | 1 |
| Mukkanti, K; Thappali, SR; Vakkalanka, SK; Varanasi, KV; Veeraraghavan, S | 1 |
| Dharmarajan, S; Dinavahi, SS; Nyayapathy, S; Perumal, Y; Viswanadha, S | 1 |
| Liang, YC; Liu, Q; Liu, T; Shi, LL; Wu, G; Wu, HG; Xue, HJ | 1 |
| Nakagawa, T; Yano, S | 1 |
| Arteaga, CL; Chanthaphaychith, S; Dahlman, K; Rexer, BN | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Antonakos, B; Cooke, VG; Danial, NN; Flemming, D; Hurov, KE; Jones, MD; Korn, JM; Ledell, J; Lehár, J; Mishina, Y; Schoumacher, M; Sellers, WR; Shao, W; Sonkin, D; Steiger, J; Stump, MD; Yan-Neale, Y | 1 |
| Alagesan, B; Bardeesy, N; Benes, CH; Contino, G; Corcoran, RB; Deshpande, V; Engelman, J; Guimaraes, AR; Hezel, AF; Loda, M; Weissleder, R; Wojtkiewicz, GR; Wong, KK | 1 |
| Liu, P; Xu, B; Zhang, C | 1 |
| Aga, MA; Kumar, B; Nagaraju, PVVS; Rayees, S; Rouf, A; Sharma, A; Singh, G; Taneja, SC | 1 |
| Abbadessa, G; Eathiraj, S; Hall, T; Schwartz, B; Wick, MJ; Yu, Y | 1 |
| Dholakia, S; Fildes, JE; Friend, PJ | 1 |
| Autret, A; Bertucci, F; Boher, JM; Camerlo, J; Campone, M; Charafe-Jauffret, E; Extra, JM; Gonçalves, A; Guerin, M; Hervieu, A; Isambert, N; Lokiec, F; Pakradouni, J; Provansal, M; Rezai, K; Sabatier, R; Viens, P | 1 |
| Adam, D; Brochiero, E; Lafayette, SL; Maillé, É; McKay, G; Messaoud, H; Nguyen, D; Ruffin, M | 1 |
| Aki, A; Baba, D; Fukuda, T; Hashimoto, M; Ishiyama, T; Katagiri, T; Muramatsu, S; Tanaka, N; Ueda, K; Watanabe, K | 1 |
| Alexe, G; Berman, JN; Boxer, MB; Conway Saur, A; Crompton, BD; Davis, MI; Guha, R; Hall, MD; Hughes, E; Hwang, EE; Kung, A; Lemieux, ME; McKnight, C; Melong, N; O'Neill, AF; Shen, M; Stegmaier, K; Veinotte, CJ; Wang, A; Wang, S; Wuerthele, K; Xu, X | 1 |
| Amico, G; Baroni, D; Brandas, C; Moran, O | 1 |
7 review(s) available for quinazolines and alpha-aminopyridine
| Article | Year |
|---|---|
New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Administration, Oral; Aminopyridines; Amrinone; Cardiotonic Agents; Coenzymes; Enoximone; Heart; Heart Failure; Hemodynamics; Humans; Imidazoles; Injections, Intravenous; Milrinone; Nifedipine; Oxyfedrine; Phosphodiesterase Inhibitors; Pyridazines; Pyridones; Quinazolines; Ubiquinone | 1986 |
The new inotropic phosphodiesterase inhibitors.
Topics: Aminopyridines; Amrinone; Calcium; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Enoximone; Heart Failure; Hemodynamics; Humans; Imidazoles; Milrinone; Myocardial Contraction; Phosphodiesterase Inhibitors; Pyridones; Quinazolines; Stimulation, Chemical; Time Factors; Xanthines | 1984 |
Vasodilator and inotropic agents in treatment of chronic cardiac failure: clinical experience and response in exercise performance.
Topics: Aerobiosis; Aminopyridines; Amrinone; Anaerobiosis; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydralazine; Neurotransmitter Agents; Physical Exertion; Piperazines; Quinazolines; Sympathetic Nervous System; Vasodilator Agents | 1981 |
[Old and new positive inotropic drugs: problems and controversies].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiotonic Agents; Glucagon; Glucosides; Heart Failure; Histamine; Humans; Imidazoles; Inosine; Quinazolines; Xanthines | 1984 |
[Positive inotropic therapy of cardiac failure: old and new drugs, controversies and tests].
Topics: Aminopyridines; Amrinone; Cardiac Glycosides; Cardiotonic Agents; Glucagon; Heart Failure; Histamine; Humans; Imidazoles; Inosine; Phosphodiesterase Inhibitors; Quinazolines; Sympathomimetics | 1984 |
New drugs in gynecologic cancer.
Topics: Aminopyridines; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cisplatin; Female; Gefitinib; Genital Neoplasms, Female; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Organoplatinum Compounds; Paclitaxel; Protein-Tyrosine Kinases; Pyrazines; Quinazolines; Trastuzumab | 2001 |
The use of kinase inhibitors in solid organ transplantation.
Topics: Aminopyridines; Humans; Immunosuppressive Agents; Indoles; Morpholines; Organ Transplantation; Oxazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Syk Kinase | 2017 |
1 trial(s) available for quinazolines and alpha-aminopyridine
| Article | Year |
|---|---|
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; France; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2017 |
26 other study(ies) available for quinazolines and alpha-aminopyridine
| Article | Year |
|---|---|
[New cardiotonic agents].
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Colforsin; Deoxyepinephrine; Humans; Imidazoles; Levodopa; Milrinone; Practolol; Prenalterol; Propanolamines; Pyridones; Quinazolines; Xamoterol | 1985 |
Synthesis and analgesic activity of some quinazoline analogs of anpirtoline.
Topics: Aminopyridines; Analgesics; Animals; Hot Temperature; Male; Mice; Mice, Inbred Strains; Molecular Structure; Pain; Piperidines; Pyridines; Quinazolines; Reaction Time; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Structure-Activity Relationship; Tramadol | 2000 |
Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation.
Topics: Aminopyridines; Animals; Antidepressive Agents, Second-Generation; Astrocytes; Butadienes; Calcium; Cells, Cultured; Chelating Agents; Dipeptides; Dose-Response Relationship, Drug; Egtazic Acid; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fluorobenzenes; Fluoxetine; Gene Expression; Indoles; Maleimides; Mice; Nitriles; Phosphorylation; Piperidines; Protein Kinase C; Proto-Oncogene Proteins c-fos; Quinazolines; Receptor, Serotonin, 5-HT2B; RNA, Messenger; Signal Transduction; Substrate Specificity; Transcriptional Activation; Tyrphostins; Up-Regulation; Urea | 2008 |
Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase.
Topics: Amino Acid Sequence; Aminopyridines; Animals; Cattle; Crystallography, X-Ray; Disease Models, Animal; Drug Design; Enzyme Inhibitors; Gene Expression; Humans; Inflammation; Isoenzymes; Male; Mice; Models, Molecular; Molecular Sequence Data; Molecular Structure; Mutation; Nitric Oxide Synthase; Quinazolines; Rats | 2008 |
Can treating the SYK cell cure leukemia?
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Regulation, Leukemic; Genomics; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; Syk Kinase; Time Factors; Tyrosine | 2009 |
Proteomic and genetic approaches identify Syk as an AML target.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genomics; HL-60 Cells; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; RNA Interference; Syk Kinase; Tandem Mass Spectrometry; Time Factors; Tumor Cells, Cultured; Tyrosine; U937 Cells; Xenograft Model Antitumor Assays | 2009 |
New drugs 2012 part I.
Topics: Aminopyridines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Benzazepines; Benzimidazoles; Benzofurans; Ceftaroline; Cephalosporins; Cyclopropanes; Drug Approval; Drug Combinations; Humans; Imidazoles; Indoles; Isoindoles; Linagliptin; Lurasidone Hydrochloride; Macrolides; Oxadiazoles; Piperazines; Proline; Purines; Quinazolines; Thiazoles; United States; Vilazodone Hydrochloride | 2012 |
Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Piperazines; Protein-Tyrosine Kinases; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Mice; Models, Molecular; Molecular Structure; Neoplasm Transplantation; Proto-Oncogene Proteins B-raf; Quinazolines; Rats; Solubility; Structure-Activity Relationship; Thiophenes; Transplantation, Heterologous | 2012 |
Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Topics: Aminopyridines; Animals; Antibodies; Antibody Specificity; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Models, Biological; Mutation; Neovascularization, Pathologic; Piperazines; Proto-Oncogene Proteins c-met; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2012 |
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Topics: Acrylamides; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Microvessels; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
Simultaneous quantitation of IC87114, roflumilast and its active metabolite roflumilast N-oxide in plasma by LC-MS/MS: application for a pharmacokinetic study.
Topics: Adenine; Aminopyridines; Animals; Benzamides; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Linear Models; Male; Quinazolines; Rats; Rats, Wistar; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
Combined inhibition of PDE4 and PI3Kδ modulates the inflammatory component involved in the progression of chronic obstructive pulmonary disease.
Topics: Adenine; Aminopyridines; Benzamides; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Cyclopropanes; Disease Progression; Humans; Lipopolysaccharides; Macrophages; Matrix Metalloproteinase 9; Neutrophils; Nicotiana; Phosphodiesterase 4 Inhibitors; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pulmonary Alveoli; Pulmonary Disease, Chronic Obstructive; Quinazolines; Smoke; U937 Cells | 2014 |
Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
Topics: Adenocarcinoma; Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Matrix Metalloproteinase 9; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; RNA, Messenger; Vascular Endothelial Growth Factor A | 2013 |
The current state of molecularly targeted drugs targeting HGF/Met.
Topics: Acrylamides; Afatinib; Aminopyridines; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrrolidinones; Quinazolines; Quinolines; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Topics: Aminopyridines; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Nude; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2014 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.
Topics: Acetamides; Aminopyridines; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Feedback, Physiological; Female; Humans; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Morpholines; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidinones; Quinazolines; ras Proteins; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Tankyrases; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Humans; MAP Kinase Kinase Kinases; Mice, Transgenic; Morpholines; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines | 2015 |
Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
Topics: Aminopyridines; Animals; Antibodies; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Lapatinib; Mice; Morpholines; ortho-Aminobenzoates; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; PTEN Phosphohydrolase; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Thiazoles; Xenograft Model Antitumor Assays | 2016 |
Synthesis of Ofornine mimics from natural product l-vasicine as anti-hypertensive agents.
Topics: Alkaloids; Aminopyridines; Animals; Antihypertensive Agents; Biological Products; Blood Pressure; Dose-Response Relationship, Drug; Female; Hypertension; Injections, Intravenous; Mice; Molecular Structure; Piperidines; Quinazolines; Rats; Rats, Wistar; Structure-Activity Relationship | 2017 |
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.
Topics: Aminopyridines; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Endometrial Neoplasms; Female; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Fibroblast Growth Factor; Xenograft Model Antitumor Assays | 2017 |
Quorum Sensing Down-Regulation Counteracts the Negative Impact of
Topics: Aminopyridines; Bacterial Proteins; Benzodioxoles; Cell Line; Cells, Cultured; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Down-Regulation; Epithelial Cells; Gene Expression Regulation, Bacterial; Humans; Infant; Mutation; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections; Quinazolines; Quorum Sensing; Respiratory System; Trans-Activators | 2017 |
Discovery of DS42450411 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4-aminopyrimidine derivatives.
Topics: Administration, Oral; Aminopyridines; Anemia; Animals; Binding Sites; Cell Line, Tumor; Drug Design; Hepcidins; Humans; Inflammation; Interleukin-6; Iron; Male; Mice, Inbred C57BL; Molecular Structure; Quinazolines; Structure-Activity Relationship | 2018 |
High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma.
Topics: Aminopyridines; Animals; Apoptosis; Aurora Kinase B; Bone Neoplasms; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Female; Focal Adhesion Kinase 1; High-Throughput Screening Assays; Humans; Indoles; Mice; Mice, Nude; Organophosphates; Protein Kinase Inhibitors; Quinazolines; Sarcoma, Ewing; Small Molecule Libraries; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zebrafish | 2019 |
Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Topics: Aminopyridines; Benzamides; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Gene Expression Regulation; HEK293 Cells; Humans; Indoles; Mutant Proteins; Mutation; Quinazolines; Thiazoles | 2019 |